Key clinical point: Elotuzumab may have synergistic clinical activity with pomalidomide against multiple myeloma.
Major finding: Median progression-free survival was 10.3 months with elotuzumab, pomalidomide, and dexamethasone vs. 4.7 months with pomalidomide and dexamethasone.
Study details: Randomized open-label phase 2 trial of 120 patients with multiple myeloma relapsed or refractory after 2 or more prior lines of therapy.
Disclosures: Bristol-Myers Squibb and AbbVie Biotherapeutics funded the study. Dr. Dimopoulos disclosed honoraria and/or consulting fees from Amgen, BMS, Celgene, Janssen and Takeda.
Source: Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.
Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.